Why some peptides are given once a week

The GLP-1 your gut produces is degraded within minutes, and yet treatments acting on its receptor are given once a week. The gap between those two timescales is not a matter of dose. It is a matter of molecular design. Closing it required solving the problem along two different routes, and each one brought its own complication.

The starting point: minutes

Endogenous GLP-1 is a 37-amino-acid peptide with a very short half-life, because the enzyme DPP-4 degrades and inactivates it. This is not a flaw in the molecule: it is how the hormone works under normal conditions.

A therapeutic peptide, by contrast, needs to remain available long enough to produce the intended effect. That is where the engineering starts, and it is what allows the medical GLP-1 weight loss programme to work on a weekly schedule.

First route: change the sequence

Before modifying anything, you have to know which part of the molecule matters. That is done with a technique called alanine scanning: each residue in the sequence is replaced with alanine and the effect is observed. If activity drops, that residue was important; if it barely changes, it was expendable.

With that map, the replaceable residues and the ends of the chain are modified until a molecule is obtained that keeps its potency and gains stability. This is the route that produced the GLP-1 analogues in use today, and it explains why the first was approved in 2005 while others followed in 2009, 2013, 2014, and 2017: every year on that list is optimisation work.

Second route: make the molecule bigger

The other strategy leaves the sequence alone and attaches something to it. It is called PEGylation, and it consists of bonding polyethylene glycol chains to the molecule.

Polyethylene glycol, or PEG, is made of repeating ethylene oxide units. For this use it has three properties that matter: it is not biodegradable, it is not toxic, and it triggers little immune response.

Its effect is mechanical. By increasing the molecule's effective molecular weight, it reduces renal clearance, the process by which the kidney filters and eliminates it. The PEG chain also physically obstructs proteolytic enzymes and makes degradation harder, and it increases the water solubility of the molecule it is attached to.

The technique has been in use since the 1970s, and more than ten PEGylated protein therapeutics are on the market.

The problem PEGylation introduced

Attaching chains is not free. Conventional PEGylation reacts at lysine or cysteine residues. When the molecule has more than one reactive residue of that kind, the attachment happens at random, producing a mixture of products with different attachment points that are also hard to separate.

The answer was to develop site-specific PEGylation methods, which allow the exact attachment point to be chosen. One such method relies on genetic code expansion: an unnatural amino acid carrying a chemical handle is introduced at the desired position, and the PEG is bonded there. The first method of this kind was published in 2004.

One example with a measurable result

Applied to human growth hormone, this approach produced twenty variants with PEG at different positions. One of them, carrying a single chain anchored at residue 35, showed efficacy and safety comparable to native hormone therapy in adults with growth hormone deficiency, but with greater potency and reduced injection frequency.

That is the effect being pursued: not changing the clinical outcome, but spacing it out.

What it means in practice

A weekly injection instead of a daily one is not a comfort detail. Adherence depends substantially on how many times you have to remember it, and the literature notes that long-acting GLP-1 analogues are administered less frequently, show fewer adverse effects, and achieve better adherence than short-acting ones. Why the oral alternative is so difficult is set out in injectable or oral.

On compounded formulations: the base active ingredient holds FDA approval in its brand-name reference medicines. Personalised compounded formulations are prepared and dispensed by state-licensed 503A pharmacies under strict individualised medical prescription following a clinical consultation. A compounded medicine is not an FDA-approved equivalent of a brand-name product.

Frequently asked questions

Why not simply give more of it so it lasts longer?

Because the problem is not quantity but the rate of destruction. The enzyme DPP-4 degrades the molecule, so giving more does not change how quickly it is eliminated. The molecule has to be modified.

Does PEGylation change what the drug does?

It is not meant to change the effect, but to prolong it. By reducing renal clearance and hindering enzymatic degradation, the molecule stays available longer.

Is this the same as an extended-release formulation?

Not quite. In extended release, what is controlled is how the drug is released from its delivery system. Here what is modified is the molecule itself, so the body eliminates it more slowly.

If it lasts longer, is it less safe?

It is available for longer, not less controlled. It remains a prescription medicine with clinical follow-up. Administration frequency is a decision for the prescribing professional.

Does it affect everyone the same way?

No. Individual results vary according to each person's biological response, and the schedule is a clinical judgement.

If you want to know whether a peptide-based treatment is right for you

A licensed professional reviews your history and your situation before any treatment is considered, and follow-up continues after the initial consultation.

Start your clinical evaluation →

Sources

1. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. *Signal Transduction and Targeted Therapy.* 2022;7(1):48. doi:10.1038/s41392-022-00904-4. Licence CC BY 4.0.
2. FDA. Compounding Laws and Policies. `https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies`

Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult your physician before making any changes to your medication or lifestyle regimen.